☰

Gheath Al-Atrash, Ph.D. - Publications

Affiliations: 
2002 University of North Texas Health Science Center at Fort Worth 
Area:
Immunology, Oncology, Molecular Biology
Tree Info Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, et al. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica. PMID 32107328 DOI: 10.3324/Haematol.2019.227371  0.323
2019 Srour SA, Saliba RM, Bittencourt MC, Ramos Perez JM, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, et al. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. American Journal of Hematology. PMID 31595538 DOI: 10.1002/Ajh.25647  0.341
2019 Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, et al. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica. PMID 30948491 DOI: 10.3324/Haematol.2018.214429  0.337
2019 Popat UR, Saliba RM, Olson A, Mehta RS, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, et al. Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.228  0.362
2018 Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, et al. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation. PMID 30258129 DOI: 10.1038/S41409-018-0344-9  0.327
2018 Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, et al. Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Advances. 2: 2254-2261. PMID 30206098 DOI: 10.1182/Bloodadvances.2018021899  0.329
2018 Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Ramos Perez JM, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, et al. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. PMID 29769261 DOI: 10.1182/Blood-2018-02-832360  0.354
2017 Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, ... Al-Atrash G, et al. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. Jci Insight. 2. PMID 28679949 DOI: 10.1172/Jci.Insight.90036  0.348
2017 Baran N, Han L, Herbrich S, Sweeney SR, Lodi A, Gay J, Feng N, Molina JR, Kaminski M, Guzman ML, Al-Atrash G, Tiziani S, Marszalek JR, Konopleva M. Novel Complex I inhibitor IACS-010759 Targets Leukemia Initiating Cells (LICs) in AML Patients Clinical Lymphoma Myeloma and Leukemia. 17: S297. DOI: 10.1016/J.Clml.2017.07.089  0.329
2016 Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, et al. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation. PMID 27991894 DOI: 10.1038/Bmt.2016.322  0.338
2016 He H, Lu S, Tallis E, Garber HR, Ding X, Ruisaard KE, Salvador B, Woods MS, John LSS, Dwyer KC, Sergueeva A, Al-Atrash G, Sukhumalchandra P, Dotti G, Ma Q, et al. Engineering a TCR-like Anti-PR1/HLA-A2 Antibody Scfv in a Novel Chimeric Antigen Receptor (CAR) to Redirect T Cells to Eliminate Myeloid Leukemia Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.594  0.301
2015 Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SO. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26524730 DOI: 10.1016/J.Bbmt.2015.10.020  0.336
2015 Gaballa S, Ge I, Fakih ROE, Brammer JE, Wang SA, Lee DA, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom AE, Al-Atrash G, Korbling M, Oran B, Kebriaei P, et al. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation Blood. 126: 152-152. DOI: 10.1182/Blood.V126.23.152.152  0.343
2015 Kerros C, Tripathi SC, Philips AV, Al-Atrash G, Ruisaard KE, Dwyer KC, Mittendorf EA, Hanash SM, Molldrem JJ. Abstract P5-04-09: Characterization of neutrophil elastase receptor in breast cancer: Implication for immunotherapy Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-04-09  0.363
2015 Kerros C, Tripathi SC, Philips AV, Al-Atrash G, Ruisaard KE, Dwyer KC, Mittendorf EA, Hanash S, Molldrem JJ. Abstract 2351: Characterization of Neutrophil elastase uptake in breast cancer: implications for immunotherapy Cancer Research. 75: 2351-2351. DOI: 10.1158/1538-7445.Am2015-2351  0.345
2014 Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 1975-81. PMID 25263628 DOI: 10.1016/J.Bbmt.2014.08.013  0.365
2013 Al-Atrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity Expert Opinion On Drug Safety. 12: 631-645. PMID 23668362 DOI: 10.1517/14740338.2013.795944  0.304
2002 Datta A, Kitson RP, Xue Y, al-Atrash G, Mazar AP, Jones TR, Goldfarb RH. Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases. In Vivo (Athens, Greece). 16: 451-7. PMID 12494889  0.494
2002 Al-Atrash G, Shetty S, Idell S, Xue Y, Kitson RP, Halady PK, Goldfarb RH. IL-2-mediated upregulation of uPA and uPAR in natural killer cells. Biochemical and Biophysical Research Communications. 292: 184-9. PMID 11890690 DOI: 10.1006/Bbrc.2002.6627  0.54
2001 Al-Atrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RH. uPA and uPAR contribute to NK cell invasion through the extracellular matrix. Anticancer Research. 21: 1697-704. PMID 11497249  0.568
2000 al-Atrash G, Kitson RP, Xue Y, Goldfarb RH. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion. In Vivo (Athens, Greece). 14: 565-70. PMID 11125540  0.551
2000 Goldfarb RH, Koelemij R, Muirhead KA, Ohlsson-Wilhelm BM, Gray BD, Kuppen PJ, Basse PH, al-Atrash G, Kitson RP. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin. In Vivo (Athens, Greece). 14: 101-4. PMID 10757065  0.561
Show low-probability matches.